A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20
← catalyst calendarNCT07792941 · readout in 166 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Basic science
Enrollment
12estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-28
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-27 | estimated | When the study began enrolling |
| Primary completion | 2027-02-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-11 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Intervention
- Drug: tilrekimig and rHuPH20
Primary outcomes
what the primary-completion date above is the date OFTilrekimig area under the serum concentration-time curve from time zero to infinity (AUCinf)
measured pre-dose, hours 12, 24, 48, 72, and 96 hours post dose. Days 8, 15, 30, 45, 60, 90, 120, and 150 post -dose
Tilrekimig Maximum Observed Plasma Concentration (Cmax)
measured pre-dose, hours 12, 24, 48, 72, and 96 hours post dose. Days 8, 15, 30, 45, 60, 90, 120, and 150 post dose
Related
PFE · their whole pipeline · Who in Congress owns PFE? · Executive-branch trades in PFE
PFE's other studiesmost recently updated first
- Safety and Efficacy of Xalkori ROS1 — · Completed
- A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight Phase 2 · Completed
- Tucatinib Continuation Study Phase 4 · Not yet recruiting
- A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases Phase 1/2 · Not yet recruiting
- A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity Phase 3 · Not yet recruiting
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed